Genex Pharmaceutical Inc
Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People's Republic of China. The RBX is a medical device that accelerates bone healing. The company distributes its medical devices to approximately 500 hospitals, as well as to other medical device customers. Genex Pharmaceutical, Inc. was founded in 2003 and is headquartered in Tianjin, the People's Rep… Read more
Genex Pharmaceutical Inc (GENX) - Total Liabilities
Latest total liabilities as of December 2007: $3.91 Million USD
Based on the latest financial reports, Genex Pharmaceutical Inc (GENX) has total liabilities worth $3.91 Million USD as of December 2007.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genex Pharmaceutical Inc - Total Liabilities Trend (2003–2007)
This chart illustrates how Genex Pharmaceutical Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genex Pharmaceutical Inc Competitors by Total Liabilities
The table below lists competitors of Genex Pharmaceutical Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SES Solar Inc
PINK:SESI
|
USA | $16.70 Million |
|
Nexis International Industries Inc
PINK:NXSI
|
USA | $11.14 Million |
|
Media Way Corp
PINK:MDAW
|
USA | $2.82 Million |
|
Protek Capital Inc.
PINK:PRPM
|
USA | $486.60K |
|
Nextmart Inc
PINK:NXMR
|
USA | $326.75K |
|
Kidville Inc
PINK:KVIL
|
USA | $6.56 Million |
|
Terme Bancorp Inc
PINK:TMEB
|
USA | $62.76K |
|
NeoMedia Technologies Inc
PINK:NEOM
|
USA | $46.30 Million |
Liability Composition Analysis (2003–2007)
This chart breaks down Genex Pharmaceutical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genex Pharmaceutical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genex Pharmaceutical Inc (2003–2007)
The table below shows the annual total liabilities of Genex Pharmaceutical Inc from 2003 to 2007.
| Year | Total Liabilities | Change |
|---|---|---|
| 2007-12-31 | $3.91 Million | +132.91% |
| 2006-12-31 | $1.68 Million | +51.84% |
| 2005-12-31 | $1.11 Million | +238.58% |
| 2004-12-31 | $326.49K | +3523.99% |
| 2003-12-31 | $9.01K | -- |